

17 November 2023

Company Announcements Office
Australian Securities Exchange

Director Retirement

Bioxyne Limited (ASX: BXN) (Bioxyne or Company) advises that Mr N H Chua has retired from the Board following the Annual General Meeting that was held today.

Tony Ho, Chairman, commented "*On behalf of the Company and my fellow directors, I would like to thank Chua for his contribution to the Bioxyne Group as Chief Executive Officer and Managing Director since 2017, and wish him well in his future endeavours*".

Mr Sam Watson will continue as sole Chief Executive Officer and Managing Director.

This announcement has been approved for release to the ASX by the Board.

For further information contact:

Anthony Ho
Chairman
Bioxyne Limited
tony@bioxyne.com

About Bioxyne

Bioxyne Limited (ASX:BXN) is an international Australian life sciences company headquartered in Sydney, and parent company of the Breathe Life Sciences Group. Bioxyne and wholly owned subsidiary [Breathe Life Sciences](#) manufacture and distribute consumer health products, patented probiotics, health supplements, therapeutic goods, and alternative medicines. In Australia, Breathe Life Sciences holds controlled substance licenses to import, export, wholesale and manufacture Schedule 3,4 and 8 poisons (Medicinal cannabis), operating a wholesale distribution model as well as direct to patient supply of prescribed medications via telemedicine platform [BLS Clinics](#). Outside of Australia, the business has manufacturing and distribution centres in Japan, the UK, and Europe, and operates direct to consumer supply of its trademarked [Dr Watson®](#) brand.

For more information on Bioxyne, please visit <https://bioxyne.com>